Parabilis Medicines Appoints Craig Tendler to Board

What Happened Parabilis Medicines, Inc. announced that on August 22, 2026 its Board increased from eight to nine members and appointed Craig Tendler as a Class II director, with a term through the 2028 annual meeting. The Board determined Mr. Tendler is independent under Nasdaq rules and named him to the Science & Technology Committee. A press release announcing the appointment was furnished on August 25, 2026.

Key Details

• Board change: number of directors increased to nine; Craig Tendler appointed as Class II director (term expires at the 2028 annual meeting).
• Compensation: Mr. Tendler received a stock option to buy 20,294 shares at $39.36 per share; the option vests in 36 substantially equal monthly installments over three years and ceases vesting if he leaves the Board.
• Cash retainer: non-employee director retainer of $40,000 annually plus $7,500 annually for Science & Technology Committee service, paid quarterly and pro-rated.
• Governance: Company entered into its standard indemnification agreement with Mr. Tendler; no related-party transactions or family relationships were reported.

Why It Matters This filing updates investors on a change in board composition and the addition of an independent director, which can affect corporate governance and oversight. The disclosed equity and cash compensation are standard for non-employee directors; the option award (20,294 shares) represents a potential small future dilution subject to vesting and continued service. No related-party issues were disclosed, which limits immediate governance concerns for shareholders.